Cargando…

Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway

This study aimed to use a population-based Prescription Database to explore later development of diabetes in women registered with gestational diabetes mellitus (GDM) and/or preeclampsia in the Medical Birth Registry of Norway (MBRN) during 2004–8. We used two nationwide Norwegian registries, the No...

Descripción completa

Detalles Bibliográficos
Autores principales: Engeland, Anders, Bjørge, Tone, Daltveit, Anne Kjersti, Skurtveit, Svetlana, Vangen, Siri, Vollset, Stein Emil, Furu, Kari
Formato: Texto
Lenguaje:English
Publicado: Springer Netherlands 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3043244/
https://www.ncbi.nlm.nih.gov/pubmed/21298469
http://dx.doi.org/10.1007/s10654-010-9527-4
_version_ 1782198612313243648
author Engeland, Anders
Bjørge, Tone
Daltveit, Anne Kjersti
Skurtveit, Svetlana
Vangen, Siri
Vollset, Stein Emil
Furu, Kari
author_facet Engeland, Anders
Bjørge, Tone
Daltveit, Anne Kjersti
Skurtveit, Svetlana
Vangen, Siri
Vollset, Stein Emil
Furu, Kari
author_sort Engeland, Anders
collection PubMed
description This study aimed to use a population-based Prescription Database to explore later development of diabetes in women registered with gestational diabetes mellitus (GDM) and/or preeclampsia in the Medical Birth Registry of Norway (MBRN) during 2004–8. We used two nationwide Norwegian registries, the Norwegian Prescription Database and the MBRN, to explore the onset of later diabetes after pregnancy complications, indicated by receiving prescriptions of drugs used to treat diabetes, in 230,000 women giving birth in 2004–8. The mean follow-up of the study cohort was 3.7 years. Five years after pregnancy, about 19 and 2% of women with GDM and preeclampsia, respectively, received drugs used to treat diabetes, compared to 0.5% of those without these complications. The risk of being dispensed drugs used to treat diabetes within the first years after pregnancy was estimated to be 41 times (95% CI: 35–47) and 3.0 times (95% CI: 2.4–3.6) higher in women with GDM and preeclampsia, respectively, compared to women without these pregnancy complications. Women with pregnancies complicated with preeclampsia or GDM had an increased risk of later diabetes, especially those having GDM. If the increase in frequency of GDM observed in MBRN in recent years is real, a further increase in diabetic women can be expected.
format Text
id pubmed-3043244
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-30432442011-04-04 Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway Engeland, Anders Bjørge, Tone Daltveit, Anne Kjersti Skurtveit, Svetlana Vangen, Siri Vollset, Stein Emil Furu, Kari Eur J Epidemiol Developmental Epidemiology This study aimed to use a population-based Prescription Database to explore later development of diabetes in women registered with gestational diabetes mellitus (GDM) and/or preeclampsia in the Medical Birth Registry of Norway (MBRN) during 2004–8. We used two nationwide Norwegian registries, the Norwegian Prescription Database and the MBRN, to explore the onset of later diabetes after pregnancy complications, indicated by receiving prescriptions of drugs used to treat diabetes, in 230,000 women giving birth in 2004–8. The mean follow-up of the study cohort was 3.7 years. Five years after pregnancy, about 19 and 2% of women with GDM and preeclampsia, respectively, received drugs used to treat diabetes, compared to 0.5% of those without these complications. The risk of being dispensed drugs used to treat diabetes within the first years after pregnancy was estimated to be 41 times (95% CI: 35–47) and 3.0 times (95% CI: 2.4–3.6) higher in women with GDM and preeclampsia, respectively, compared to women without these pregnancy complications. Women with pregnancies complicated with preeclampsia or GDM had an increased risk of later diabetes, especially those having GDM. If the increase in frequency of GDM observed in MBRN in recent years is real, a further increase in diabetic women can be expected. Springer Netherlands 2011-02-06 2011 /pmc/articles/PMC3043244/ /pubmed/21298469 http://dx.doi.org/10.1007/s10654-010-9527-4 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Developmental Epidemiology
Engeland, Anders
Bjørge, Tone
Daltveit, Anne Kjersti
Skurtveit, Svetlana
Vangen, Siri
Vollset, Stein Emil
Furu, Kari
Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway
title Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway
title_full Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway
title_fullStr Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway
title_full_unstemmed Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway
title_short Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway
title_sort risk of diabetes after gestational diabetes and preeclampsia. a registry-based study of 230,000 women in norway
topic Developmental Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3043244/
https://www.ncbi.nlm.nih.gov/pubmed/21298469
http://dx.doi.org/10.1007/s10654-010-9527-4
work_keys_str_mv AT engelandanders riskofdiabetesaftergestationaldiabetesandpreeclampsiaaregistrybasedstudyof230000womeninnorway
AT bjørgetone riskofdiabetesaftergestationaldiabetesandpreeclampsiaaregistrybasedstudyof230000womeninnorway
AT daltveitannekjersti riskofdiabetesaftergestationaldiabetesandpreeclampsiaaregistrybasedstudyof230000womeninnorway
AT skurtveitsvetlana riskofdiabetesaftergestationaldiabetesandpreeclampsiaaregistrybasedstudyof230000womeninnorway
AT vangensiri riskofdiabetesaftergestationaldiabetesandpreeclampsiaaregistrybasedstudyof230000womeninnorway
AT vollsetsteinemil riskofdiabetesaftergestationaldiabetesandpreeclampsiaaregistrybasedstudyof230000womeninnorway
AT furukari riskofdiabetesaftergestationaldiabetesandpreeclampsiaaregistrybasedstudyof230000womeninnorway